The Scene
A storefront for the things that save mothers
Somewhere this morning, a procurement officer for a health ministry opens a browser, clicks through a catalog, and adds an anti-shock garment to a cart. Not a pair of sneakers. A neoprene garment that, wrapped around a hemorrhaging mother, can hold off death long enough for her to reach a surgeon. The checkout looks ordinary. The cargo is not.
That cart belongs to Maternova - a small, woman-run company in Providence, Rhode Island that decided the world's most life-saving maternal and newborn technologies were stuck in the wrong place: in research papers, in inventors' garages, in pilot programs that ended when the grant did. Maternova's whole job is to move them. It curates, vets, markets, and ships evidence-based medical devices and diagnostics into the places where a birth is still the most dangerous thing a woman will ever do.
Today the company says it has reached 4.1 million mothers and infants across more than 65 countries. It runs lean - roughly a dozen people - and it sells, of all things, hope by the unit. The irony is hard to miss: the hardest problem in global health turned out to need something deeply unglamorous. A good store.
The Problem They Saw
Brilliant inventions, no road to the bedside
Here is the quiet scandal at the center of global health: the device gets invented, the trial gets published, the award gets won - and then nothing happens. A clever bilirubinometer for newborn jaundice sits in a lab. A bubble CPAP machine that could save a premature baby's lungs exists in a single hospital. The mother in the rural clinic never sees any of it.
The gap was not science. It was logistics, distribution, and the unromantic plumbing of supply. Manufacturers would only run production in batches of 5,000 or 10,000 units. Most buyers - a clinic here, an NGO there - wanted to try one before betting on a thousand. So the order never cleared the minimum, the run never happened, and the invention quietly died of market failure. Postpartum hemorrhage, meanwhile, kept killing a woman roughly every several minutes, most of those deaths preventable with tools that already existed.
Maternova was built to stand exactly in that gap - the maddening, fatal space between "this works" and "this is here."
The Founders' Bet
What if a marketplace could do what charity couldn't?
Meg Wirth had spent years watching the gap from the inside. With a Harvard degree, a Princeton public-policy MPA, and stints at the Rockefeller Foundation and a Gates-funded social-venture fund, she had reviewed global-health technologies for a living - and kept noticing the same dead end. The good ideas never reached the field. In 2009 she stopped reviewing and started building.
Her bet was contrarian. Not another nonprofit dependent on the next grant cycle, but a for-profit social enterprise - a business that had to survive by being useful. Maternova launched as the first e-commerce marketplace dedicated to global-health technology: an online index of more than 200 innovations, and a checkout that connected the inventors who had no distribution to the buyers who had no catalog.
The structural twist is the part that makes accountants squint. Less than 49% of profits flow to investors; the rest is plowed back into R&D, scaling manufacturers, and even midwife-training schools. A company designed, on purpose, to keep most of its own money. Capitalism with a conscience, or a conscience with an invoice - take your pick.
2009
Founded in Providence, RI by Meg Wirth
<49%
Share of profit that flows to investors - the rest is reinvested
~11
Employees running a 65-country operation
200+
Innovations tracked in the original Innovation Index
FIG. 1 - The math of a company built to under-pay its own shareholders. By design.
"Manufacturers will only produce in runs of 5,000 or 10,000. So we pull together NGOs and combine their orders to unlock the minimum quantity."
- Meg Wirth, on demand aggregation
The Product
A catalog where every item is a small argument against dying
Maternova does not invent most of what it sells - it finds, tests, and champions it. The genius is editorial: deciding what is good enough to carry. The shelf reads like a field manual for the worst moments of childbirth, each product a counter to a specific way the day can go wrong.
NASG Anti-Shock Garment
A nine-segment neoprene-and-Velcro wrap that squeezes blood toward the heart and brain, reversing the shock of postpartum hemorrhage long enough to reach care.
MaternaWell Tray
A reusable tray that catches and measures blood loss at birth - so "she's bleeding a lot" becomes an actual number. Now echoed in 2025 WHO guidance.
CRADLE Vital Signs Alert
A blood-pressure device that runs a shock-index calculation and flashes a traffic light: green, yellow, red. Validated by King's College London.
Pumani Bubble CPAP
Low-cost respiratory support for premature newborns in distress and small children, where ventilators are a fantasy.
BiliDx Bilirubinometer
A heel-stick jaundice reader giving lab-quality bilirubin results in about ten minutes, ~600 tests per battery charge.
Pratt Pouch
A foil packet the size of a ketchup sachet that keeps an antiretroviral dose stable for a year - handed to HIV-exposed infants within a day of birth.
FIG. 2 - Six entries from a catalog where "add to cart" is doing a lot of moral work.
Around the headliners sit the rapid diagnostics - point-of-care tests for preeclampsia, sepsis, urinary infection, schistosomiasis, dengue, and malaria - plus fetal dopplers, resuscitation kits, and infant warmers. Boring, until the day one of them is the only thing in the room standing between a patient and a statistic.
The Proof
The numbers that survived contact with the field
Impact claims are cheap. Maternova's case rests on a few that it has put in writing - a decade-long reach figure, a country count that keeps climbing, and a buyer network that turns scattered demand into orders factories will actually fill. The chart below is the company's own argument, drawn to scale.
Maternova, by the numbers
// reported figures - bars scaled for comparison, not a shared axis
FIG. 3 - The 10,000-unit "factory minimum" is the whole problem in one bar: too big for any single clinic, which is why Maternova pools the orders.
Then there is the validation that comes from outside the building. The CRADLE device was developed and tested by King's College London. The Pratt Pouch came out of Duke's engineering school. The CRADLE manufacturing partnership runs through Microlife. And in 2025, the MaternaWell Tray got the rarest endorsement of all - international clinical guidelines, when WHO, FIGO, and ICM updated postpartum-hemorrhage guidance to recognize tray-style blood-loss measurement. The award shelf is crowded too: Bloomberg, Katerva, Women Deliver, a Cartier Women's Initiative finalist nod for Wirth.
The Mission & The People
Run by people who have stood in the clinic
In 2023 the company handed the wheel to someone who had spent her career on the receiving end of products like these. Dr. M. Gabriela Salvador - MD from Argentina, MPH from Harvard, a former pediatric ophthalmologist - had run roughly 100 clinics across five Latin American countries with Pro Mujer and led global operations at Americares. She did not arrive to learn what a low-resource ward needs. She arrived already knowing.
That is the through-line of Maternova's culture: a refusal to treat the field as abstract. The mission statement is plain to the point of being unmarketable - accelerate access to life-saving innovation by educating, marketing, distributing, and evaluating. No moonshot language. Just the four unglamorous verbs that actually move a device from a paper to a patient.
Why It Matters Tomorrow
The gap is still open
The unfair truth of maternal health is that the science is mostly solved. We know how to stop the bleeding, how to read the vitals, how to keep the premature lungs going. What remains is distribution - the least exciting word in medicine, and the one that still decides who lives. Every year there are new devices, new diagnostics, new clever fixes. Every year most of them stall at the same gap Maternova was built to cross.
Which is why a small company with a dozen people and a good catalog is not a footnote. It is a working theory: that the market, pointed correctly, can carry care the last and hardest mile. The theory keeps getting tested - by guidelines that adopt its products, by investors who back the model, by 65 countries and counting.
Back to the cart
That procurement officer clicks "place order." Somewhere downstream, a clinic that could never have hit a factory minimum gets a box it could actually afford - because a hundred orders like hers were quietly stacked together to unlock the run.
The checkout still looks ordinary. The mother who reaches that clinic next week will never know the name Maternova, never see the marketplace, never read the guidelines. She will simply not become a number. Which was, all along, the entire point of building a store.
